Search Results - "British journal of cancer"

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy by Raskov, Hans, Orhan, Adile, Christensen, Jan Pravsgaard, Gögenur, Ismail

“…The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface…”
Get full text

Cancer health disparities in racial/ethnic minorities in the United States by Zavala, Valentina A., Bracci, Paige M., Carethers, John M., Carvajal-Carmona, Luis, Coggins, Nicole B., Cruz-Correa, Marcia R., Davis, Melissa, de Smith, Adam J., Dutil, Julie, Figueiredo, Jane C., Fox, Rena, Graves, Kristi D., Gomez, Scarlett Lin, Llera, Andrea, Neuhausen, Susan L., Newman, Lisa, Nguyen, Tung, Palmer, Julie R., Palmer, Nynikka R., Pérez-Stable, Eliseo J., Piawah, Sorbarikor, Rodriquez, Erik J., Sanabria-Salas, María Carolina, Schmit, Stephanie L., Serrano-Gomez, Silvia J., Stern, Mariana C., Weitzel, Jeffrey, Yang, Jun J., Zabaleta, Jovanny, Ziv, Elad, Fejerman, Laura

“…There are well-established disparities in cancer incidence and outcomes by race/ethnicity that result from the interplay between structural, socioeconomic,…”
Get full text

Reprogramming of fatty acid metabolism in cancer by Koundouros, Nikos, Poulogiannis, George

“…A common feature of cancer cells is their ability to rewire their metabolism to sustain the production of ATP and macromolecules needed for cell growth,…”
Get full text

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer by Leonetti, Alessandro, Sharma, Sugandhi, Minari, Roberta, Perego, Paola, Giovannetti, Elisa, Tiseo, Marcello

“…Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-…”
Get full text

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours by Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.

“…Background In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of…”
Get full text

Deep learning in cancer pathology: a new generation of clinical biomarkers by Echle, Amelie, Rindtorff, Niklas Timon, Brinker, Titus Josef, Luedde, Tom, Pearson, Alexander Thomas, Kather, Jakob Nikolas

“…Clinical workflows in oncology rely on predictive and prognostic molecular biomarkers. However, the growing number of these complex biomarkers tends to…”
Get full text

Cytokines in clinical cancer immunotherapy by Berraondo, Pedro, Sanmamed, Miguel F., Ochoa, María C, Etxeberria, Iñaki, Aznar, Maria A., Pérez-Gracia, José Luis, Rodríguez-Ruiz, María E., Ponz-Sarvise, Mariano, Castañón, Eduardo, Melero, Ignacio

“…Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the discovery of the potent anti-tumour activities of several pro-inflammatory…”
Get full text

The lingering mysteries of metastatic recurrence in breast cancer by Riggio, Alessandra I., Varley, Katherine E., Welm, Alana L.

“…Despite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic…”
Get full text

Mechanisms of resistance to immune checkpoint inhibitors by Jenkins, Russell W, Barbie, David A, Flaherty, Keith T

“…Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are…”
Get full text

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets by Han, Sue, Liu, Yang, Cai, Sabrina J., Qian, Mingyu, Ding, Jianyi, Larion, Mioara, Gilbert, Mark R., Yang, Chunzhang

“…Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular…”
Get full text

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression by Groth, Christopher, Hu, Xiaoying, Weber, Rebekka, Fleming, Viktor, Altevogt, Peter, Utikal, Jochen, Umansky, Viktor

“…Under steady-state conditions, bone marrow-derived immature myeloid cells (IMC) differentiate into granulocytes, macrophages and dendritic cells (DCs). This…”
Get full text

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond by Keller, Laura, Belloum, Yassine, Wikman, Harriet, Pantel, Klaus

“…Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The majority of currently available studies on the use of this…”
Get full text

The clinical role of the TME in solid cancer by Giraldo, Nicolas A., Sanchez-Salas, Rafael, Peske, J. David, Vano, Yann, Becht, Etienne, Petitprez, Florent, Validire, Pierre, Ingels, Alexandre, Cathelineau, Xavier, Fridman, Wolf Herman, Sautès-Fridman, Catherine

“…The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial…”
Get full text

Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression by Lüönd, Fabiana, Tiede, Stefanie, Christofori, Gerhard

“…Heterogeneity within a tumour increases its ability to adapt to constantly changing constraints, but adversely affects a patient’s prognosis, therapy response…”
Get full text

New aspects of amino acid metabolism in cancer by Vettore, Lisa, Westbrook, Rebecca L., Tennant, Daniel A.

“…An abundant supply of amino acids is important for cancers to sustain their proliferative drive. Alongside their direct role as substrates for protein…”
Get full text

Achieving clinical success with BET inhibitors as anti-cancer agents by Shorstova, Tatiana, Foulkes, William D., Witcher, Michael

“…The transcriptional upregulation of oncogenes is a driving force behind the progression of many tumours. However, until a decade ago, the concept of ‘switching…”
Get full text

TAMeless traitors: macrophages in cancer progression and metastasis by Aras, Shweta, Zaidi, M Raza

“…Macrophages are conventionally classified into M1 and M2 subtypes according to their differentiation status and functional role in the immune system. However,…”
Get full text

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance by Krook, Melanie A., Reeser, Julie W., Ernst, Gabrielle, Barker, Hannah, Wilberding, Max, Li, Gary, Chen, Hui-Zi, Roychowdhury, Sameek

“…Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of…”
Get full text

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms by Sahin, Ibrahim Halil, Akce, Mehmet, Alese, Olatunji, Shaib, Walid, Lesinski, Gregory B., El-Rayes, Bassel, Wu, Christina

“…Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics…”
Get full text

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 by Mehra, Ranee, Seiwert, Tanguy Y., Gupta, Shilpa, Weiss, Jared, Gluck, Iris, Eder, Joseph P., Burtness, Barbara, Tahara, Makoto, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Geva, Ravit, Chung, Hyun Cheol, Lin, Chia-Chi, Aurora-Garg, Deepti, Ray, Archana, Pathiraja, Kumudu, Cheng, Jonathan, Chow, Laura Q. M., Haddad, Robert

“…Background Second-line treatment options for advanced head and neck squamous cell carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the…”
Get full text